Abstract
A 10-year cohort study was performed, involving all of the 118 patients treated with bucillamine in our hospital between 1988 and 1990. Evaluation was made on the basis of erythrocyte sedimentation rate, grip strength, joint score, duration of morning stiffness, and Lansbury index consisting of the above four parameters. Eleven patients were male and 107 were female, with a mean age of 53 years (range: 20–79 years) and a mean duration of illness of 8.2 years (range: 2–31 years). Lansbury index remained significantly suppressed throughout the 10-year period of treatment. Continuous treatment was possible for 10 years in 18 patients (15%: 2 men and 16 women). Stage of disease did not advance in 14 patients. Six patients met the criteria for remission. Of all patients, 50% dropped out of treatment at 2.4 years after the start of treatment and 75% at 5 years. The 100 patients who dropped out could be roughly divided into three groups. One third of them dropped out because of lack of or attenuation of response. Another third dropped out because of referral to other medical facilities or discontinuation of visits to our hospital, and the remaining third dropped out because of adverse reactions to treatment. There was no particular trend in terms of sex, age, duration of sickness, drugs used before bucillamine, or level of activity of rheumatoid arthritis. There were no significant difference in the stage and class of the disease, and other backgrounds between 10-year treatment group and dropout group.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
InstitutionalAuthorNameMinistry of Health, Labour, and Welfare (MHLW) Study Group (2004) Manual for the diagnosis and treatment of rheumatoid arthritis (revised edition) – Diagnostic manuals and evidence-based guidelines on diagnosis and treatment (in Japanese) Japan Rheumatism Foundation Tokyo
K Nishimura S Uchida F Watanabe (1993) ArticleTitleLong-term results of bucillamine in rheumatoid arthritis – Five-year results and prediction of responses at early stages of administration (in Japanese) Jpn J Inflamm 13 293–9
M Saito T Nagasawa (1998) ArticleTitleComparison of usefulness in the treatment of rheumatoid arthritis among DMARDs by the life table method (in Japanese) J Clin Exp Med 186 139–43
H Mitsuhashi K Banpa (2001) ArticleTitleLong-term results of bucillamine in rheumatoid arthritis (in Japanese) Clin Rheumatol Relat Res 13 268–74
ME Weinblatt AL Maier PA Fraser JS Coblyn (1998) ArticleTitleLongterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy J Rheumatol 25 238–42 Occurrence Handle9489813 Occurrence Handle1:CAS:528:DyaK1cXhtVGgu7w%3D
InstitutionalAuthorNameAmerican College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines (2002) ArticleTitleGuidelines for the Management of Rheumatoid Arthritis 2002 Update Arthritis Rheum 46 328–46 Occurrence Handle10.1002/art.10148
Wyeth KK Information for proper use of Rheumatrex vol. 11 (in Japanese). 2006
Santen Pharmaceutical Co. Ltd. Summary of adverse reactions to Rimatil (in Japanese). 2006
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Yokota, N., Kuga, Y., Kanazawa, T. et al. Ten years results of bucillamine in the treatment of rheumatoid arthritis. Mod Rheumatol 17, 33–36 (2007). https://doi.org/10.1007/s10165-006-0533-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10165-006-0533-z